Blatt, Sebastian;
Krüger, Maximilian;
Kämmerer, Peer W.;
Thiem, Daniel G. E.;
Matheis, Philipp;
Eisenbeiß, Anne-Katrin;
Wiltfang, Jörg;
Al-Nawas, Bilal;
Naujokat, Hendrik
Non-Interventional Prospective Observational Study of Platelet Rich Fibrin as a Therapy Adjunctive in Patients with Medication-Related Osteonecrosis of the Jaw
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Non-Interventional Prospective Observational Study of Platelet Rich Fibrin as a Therapy Adjunctive in Patients with Medication-Related Osteonecrosis of the Jaw
Beteiligte:
Blatt, Sebastian;
Krüger, Maximilian;
Kämmerer, Peer W.;
Thiem, Daniel G. E.;
Matheis, Philipp;
Eisenbeiß, Anne-Katrin;
Wiltfang, Jörg;
Al-Nawas, Bilal;
Naujokat, Hendrik
Erschienen:
MDPI AG, 2022
Erschienen in:
Journal of Clinical Medicine, 11 (2022) 3, Seite 682
Sprache:
Englisch
DOI:
10.3390/jcm11030682
ISSN:
2077-0383
Entstehung:
Hochschulschrift:
Anmerkungen:
Beschreibung:
<jats:p>Background: Medication-related osteonecrosis (MRONJ) of the jaw is a severe and feared side effect of antiresorptive therapy in the oncological setting. With growing evidence that impaired angiogenesis may represent a key factor in pathogenesis, the aim of this study was to evaluate an autologous platelet concentrate as a possible additive in surgical therapy to optimize vascularization and, subsequently, resolution rates. Material and Methods: A non-interventional, prospective, multicenter study was conducted, and all patients with stage I-III MRONJ, undergoing antiresorptive therapy for an oncological indication, were included. The necrosis was treated surgically without (study arm A) or with (arm B) the addition of an autologous platelet concentrate (platelet-rich fibrin, PRF). Results: After 5, 14, and 42 days postoperative, wound healing (primary outcome: mucosal integrity) as well as downstaging, pain perception, and oral health-related quality of life (secondary outcome) were assessed via clinical evaluation. Among the 52 patients included, primarily with MRONJ stage I and II, the use of PRF as an additive in surgical therapy did not display a significant advantage for wound healing (p = 0.302), downstaging (p = 0.9), pain reduction (p = 0.169), or quality of life (p = 0.9). Summary: In conclusion, PRF as an adjunct did not significantly optimize wound healing. Further, no significant changes in terms of downstaging, pain sensation, and oral health-related quality of life were found.</jats:p>